- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.70 Å
- Oligo State
- hetero-8-8-mer
- Ligands
- 4 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 8 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-FUC.2: 4 residues within 4Å:- Chain C: N.52, V.69, S.117, E.119
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:S.117, C:N.52
- Water bridges: C:N.52
NAG-FUC.5: 4 residues within 4Å:- Chain E: P.154, C.171, N.172, T.173
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:T.173, E:T.173
NAG-FUC.6: 4 residues within 4Å:- Chain G: N.52, T.67, S.117, E.119
4 PLIP interactions:1 interactions with chain G, 3 interactions with chain H- Hydrophobic interactions: G:T.67
- Hydrogen bonds: G:N.52, G:N.52, H:D.3, H:Y.8, H:L.9, G:H.251
NAG-FUC.8: 5 residues within 4Å:- Chain G: T.226, G.227, T.228, N.233, H.260
1 PLIP interactions:1 interactions with chain G- Hydrogen bonds: G:G.227
- Water bridges: G:H.260
NAG-FUC.9: 6 residues within 4Å:- Chain I: N.52, V.69, R.83, V.85, S.117, E.119
1 PLIP interactions:1 interactions with chain I- Hydrogen bonds: I:R.83, I:V.85, I:S.117, I:S.117, I:N.52
NAG-FUC.11: 5 residues within 4Å:- Chain I: T.226, G.227, T.228, N.233, H.260
2 PLIP interactions:2 interactions with chain I- Hydrophobic interactions: I:T.226
- Hydrogen bonds: I:N.233
NAG-FUC.14: 4 residues within 4Å:- Chain M: N.52, V.69, S.117, E.119
1 PLIP interactions:1 interactions with chain M- Hydrogen bonds: M:S.117, M:S.117, M:N.52
NAG-FUC.17: 4 residues within 4Å:- Chain O: N.52, V.69, S.117, E.119
2 PLIP interactions:2 interactions with chain O- Hydrogen bonds: O:S.117, O:S.117
- 2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 4 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.10: 3 residues within 4Å:- Chain I: I.130, N.162, F.211
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.13: 2 residues within 4Å:- Chain K: N.162, F.211
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.15: 2 residues within 4Å:- Chain M: N.162, F.211
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.18: 3 residues within 4Å:- Chain O: I.130, N.162, F.211
No protein-ligand interaction detected (PLIP)- 11 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.19: 3 residues within 4Å:- Chain A: N.162, D.163, F.211
No protein-ligand interaction detected (PLIP)NAG.20: 2 residues within 4Å:- Chain A: P.154, N.172
No protein-ligand interaction detected (PLIP)NAG.24: 3 residues within 4Å:- Chain C: I.130, N.162, F.211
3 PLIP interactions:3 interactions with chain C- Hydrophobic interactions: C:F.211
- Hydrogen bonds: C:I.130, C:N.162
NAG.25: 2 residues within 4Å:- Chain C: P.154, N.172
1 PLIP interactions:1 interactions with chain C- Hydrogen bonds: C:N.172
NAG.29: 4 residues within 4Å:- Chain E: I.130, Q.131, N.162, F.211
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:Q.131
NAG.33: 2 residues within 4Å:- Chain G: P.154, N.172
No protein-ligand interaction detected (PLIP)NAG.38: 1 residues within 4Å:- Chain I: N.172
No protein-ligand interaction detected (PLIP)NAG.42: 1 residues within 4Å:- Chain K: N.172
No protein-ligand interaction detected (PLIP)NAG.43: 2 residues within 4Å:- Chain K: N.233, H.260
No protein-ligand interaction detected (PLIP)NAG.46: 3 residues within 4Å:- Chain M: T.228, N.233, H.260
No protein-ligand interaction detected (PLIP)NAG.49: 1 residues within 4Å:- Chain O: N.172
No protein-ligand interaction detected (PLIP)- 21 x SO4: SULFATE ION(Non-functional Binders)
SO4.21: 2 residues within 4Å:- Chain A: K.7
- Chain C: R.13
Ligand excluded by PLIPSO4.22: 6 residues within 4Å:- Chain A: K.50, R.53, P.151, H.249, A.250, H.251
Ligand excluded by PLIPSO4.23: 4 residues within 4Å:- Chain A: R.58, Q.111
- Chain I: R.58, Q.111
Ligand excluded by PLIPSO4.26: 6 residues within 4Å:- Chain C: E.49, R.53, P.151, H.249, A.250, H.251
Ligand excluded by PLIPSO4.27: 4 residues within 4Å:- Chain C: R.58, Q.111
- Chain O: R.58, Q.111
Ligand excluded by PLIPSO4.28: 5 residues within 4Å:- Chain C: T.164, H.166, A.255, F.256, S.257
Ligand excluded by PLIPSO4.30: 7 residues within 4Å:- Chain E: E.49, K.50, P.151, Q.248, H.249, A.250, H.251
Ligand excluded by PLIPSO4.31: 4 residues within 4Å:- Chain E: R.58, Q.111
- Chain M: R.58, Q.111
Ligand excluded by PLIPSO4.32: 6 residues within 4Å:- Chain E: W.129, T.164, H.166, A.255, F.256, S.257
Ligand excluded by PLIPSO4.34: 2 residues within 4Å:- Chain E: K.7
- Chain G: R.13
Ligand excluded by PLIPSO4.35: 6 residues within 4Å:- Chain G: K.50, R.53, P.151, H.249, A.250, H.251
Ligand excluded by PLIPSO4.36: 4 residues within 4Å:- Chain G: R.58, Q.111
- Chain K: R.58, Q.111
Ligand excluded by PLIPSO4.37: 5 residues within 4Å:- Chain G: T.164, H.166, K.198, F.256, S.257
Ligand excluded by PLIPSO4.39: 2 residues within 4Å:- Chain I: R.13
- Chain O: K.7
Ligand excluded by PLIPSO4.40: 7 residues within 4Å:- Chain I: E.49, R.53, P.151, Q.248, H.249, A.250, H.251
Ligand excluded by PLIPSO4.41: 6 residues within 4Å:- Chain I: W.129, T.164, H.166, K.198, F.256, S.257
Ligand excluded by PLIPSO4.44: 2 residues within 4Å:- Chain K: K.7
- Chain M: R.13
Ligand excluded by PLIPSO4.45: 7 residues within 4Å:- Chain K: E.49, R.53, P.151, Q.248, H.249, A.250, H.251
Ligand excluded by PLIPSO4.47: 6 residues within 4Å:- Chain M: K.50, R.53, P.151, H.249, A.250, H.251
Ligand excluded by PLIPSO4.48: 6 residues within 4Å:- Chain M: T.164, H.166, V.238, A.255, F.256, S.257
Ligand excluded by PLIPSO4.50: 7 residues within 4Å:- Chain O: E.49, R.53, P.151, Q.248, H.249, A.250, H.251
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Llinas, P. et al., Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. (2005)
- Release Date
- 2005-05-10
- Peptides
- Urokinase plasminogen activator surface receptor: ACEGIKMO
antagonist peptide: BDFHJLNP - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CE
EG
GI
IK
KM
MO
OB
BD
DF
FH
HJ
JL
LN
NP
P
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.70 Å
- Oligo State
- hetero-8-8-mer
- Ligands
- 4 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 8 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 4 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 11 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 21 x SO4: SULFATE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Llinas, P. et al., Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. (2005)
- Release Date
- 2005-05-10
- Peptides
- Urokinase plasminogen activator surface receptor: ACEGIKMO
antagonist peptide: BDFHJLNP - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CE
EG
GI
IK
KM
MO
OB
BD
DF
FH
HJ
JL
LN
NP
P